Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Cancer Medicines Report Highlights How Far There Is Still To Go

The report released today by Te Aho o Te Kahu (the Cancer Control Agency) Understanding the Gap: an analysis of the availability of cancer medicines in Aotearoa is a small step in the right direction, but there is still a long way to go.

Bowel Cancer New Zealand general manager Rebekah Heal says, “Imagine re-mortgaging your home so your family can spend another Christmas together. This report covers the bare minimum of what medicines are needed. People who have been told they have bowel cancer and need unfunded drugs come under huge financial pressure at an extremely difficult time.”

After 20 years of no new funded bowel cancer drugs, only Cetuximab was identified as deserving of funding in the report, and even that was limited to first-line therapy. In particular, Bevacizumab has been shown to increase survivability and is funded in Australia but was not included in today’s report.

Bowel Cancer New Zealand medical advisor and oncologist Dragan Damianovich says, “This analysis has failed to show the actual gaps in survival between New Zealand and other OECD countries, particularly Australia. We know approximately 40 per cent of New Zealand bowel cancer sufferers die from this cancer every year compared to 25 per cent in Australia.”

This report highlights the urgency needed for the Government to increase Pharmac funding for bowel cancer drugs.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

Dr Damianovich says, “We need look no further than what is spent on medicines in this country. Relative to GDP, NZ spends only 0.34 per cent on medicines (OECD 1.4 per cent), NZ spends only 5.4 per cent of the total health budget on medicines (OECD 16 per cent), and NZ spends US$136 per capita (OECD US$647). Of 36 OECD countries, only Mexico spends less than NZ.”

Heal says, “It’s time for change. At the moment, Pharmac uses its statutory objective to decide which drugs it funds. But the problem is patients don’t have a say in this. At Bowel Cancer New Zealand, we know how desperately this needs to change. The sad truth about advanced bowel cancer in this country is that time really is money."

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.